Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVISR: Add-on vs Switch to Vibegron in OAB with Inadequate Antimuscarinic Response
jRCTs031240134Recruiting
- Sponsor
- Kyorin Pharmaceutical
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of vibegron in overactive bladder (OAB) (2 arms), sponsored by Kyorin Pharmaceutical. Primary endpoint: Change in daily urination frequency at 12 weeks between groups. Started Jun 2024; status: recruiting.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on jRCTs031240134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240134.